



JUNE 2023

NORWAY TRANSPARENCY ACT STATEMENT



Our Commitment to Sustainability

A sustainable future starts with health. It is the foundation of everything we can do in life — as individuals, families and communities. It helps societies prosper and fuels thriving economies.

For more than 135 years, we've been improving people's health at all ages and stages of life — tackling some of the world's most pressing problems with innovative products and technologies.

At Abbott, sustainability means running our business to have a long-term impact for the people we serve — shaping the future of healthcare and helping more people live healthier, better lives.

Our 2030 Sustainability Plan is focused on designing our life-changing technologies and products for accessibility to reach more people in more places than ever before. We're also working across our business and in partnership with others to break down barriers to access and continue to build a more sustainable business through all the steps we take, every day. Abbott's global portfolio of products includes:



135
DISCOVERING NEW
WAYS TO MAKE LIFE
BETTER FOR 135 YEARS



160+
MAKING A DIFFERENCE
IN OVER 160 COUNTRIES



115K
EMPLOYEES WORKING
AROUND THE WORLD
TO MAKE A LASTING
IMPACT ON HEALTH

LIFE-CHANGING TECHNOLOGIES

MARKET-LEADING POSITIONS IN EVERY BUSINESS

CARDIOVASCULAR CARE

Keeping your heart healthy with medical technologies that help you and your doctor better manage your health

- #1 Remote heart-failure monitoring
- #1 Transcatheter mitral-valve repair
- #1 Heart pumps (LVADs)
- #1 Stents



DIAGNOSTICS

Providing the information you need when you need it, so you and your doctor can make better decisions

- #1 Point-of-care testing
 - #1 Infectious disease testing
 - #1 Blood and plasma serology screening
- A leader in COVID-19 testing



DIABETES CARE

Giving people with diabetes the freedom to continuously monitor and track their glucose levels with unsurpassed 14-day accuracy and no painful fingersticks.^{1,2}

- #1 Continuous glucose monitoring³



NUTRITION

Nourishing and supporting your health, at every stage of life

- #1 Adult nutrition
- #1 Brand fed in hospitals (U.S.)⁴



NEUROMODULATION CARE

Treating chronic pain and movement disorders by targeting specific areas of the spinal cord and brain

A leader in chronic-pain devices



BRANDED GENERIC MEDICINES

Helping people in emerging countries get and stay healthy

- #1 Pancreatic enzyme deficiency treatment
- #1 Progesterone hormone therapy
- #1 Vertigo treatment



1. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

2. FreeStyle Libre Indications and Important Safety Information: <https://www.freestylelibre.us/safety-information.html>

3. Data on file. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.

4. Similac is the #1 brand fed in U.S. hospitals; data on file.

Abbott in Norway

ADVANCING HEALTH AND WELLNESS IN NORWAY

Abbott has been dedicated to helping people in Norway live healthier lives since 1979 by developing a diverse range of diagnostic tools, diabetes care products, cardiovascular devices and neuromodulation care treatments.

With approximately 400 employees at our three sites and in our sales activities throughout Norway, Abbott in Norway reflects our dedication to manufacturing the highest-quality products and finding lasting solutions to health challenges.

From developing diagnostic tests to ensure patients can benefit from the latest treatments to creating state-of-the-art medical devices available to healthcare professionals and patients, we are at the forefront of science and innovation in everything we do.

DELIVERING WORLD-CLASS PRODUCTS

Abbott offers a wide variety of leading products in Norway to help people live healthier lives.



DIAGNOSTICS

Diagnostic testing is a compass, providing information that helps in the prevention, diagnosis and treatment of a wide range of health conditions. Abbott's life-changing tests, diagnostic tools and blood tests put the power of health in the hands of people everywhere. We're empowering smarter medical decisions to help transform the way you take care of your health at every stage of life.



NEUROMODULATION CARE

Chronic pain and movement disorders can disrupt daily routines and prevent people from living their lives. Neuromodulation care treats chronic pain and movement disorders by targeting specific areas of the spinal cord and brain. Every day, our technologies improve the quality of life of people around the world.



DIABETES CARE

We believe that people with diabetes should enjoy the freedom to lead healthier, more active lives. We're committed to creating innovative technologies that help people with diabetes better manage their conditions. We're revolutionizing the way people monitor their glucose with accurate, easy-to-use diabetes products.



CARDIOVASCULAR CARE

A healthy cardiovascular system is essential for good health. We are advancing the treatment of heart and vascular diseases through innovative medical technologies that are less invasive, allowing people to regain their health and be able to move forward with their lives.

Abbott in Norway



Abbott Laboratories, (“Abbott”), headquartered in Abbott Park, Illinois, USA, is the ultimate parent company of each of the entities comprising Abbott Norway. Abbott is a globally diversified healthcare company with a central purpose of helping people live their healthiest possible lives through our broad portfolio of products.

This statement is made pursuant to the Norway Transparency Act and applies to the following legal entities:

Abbott Norge AS
Abbott Medical Norway AS
Abbott Diagnostics Technologies AS
Abbott Rapid Diagnostics AS
Axis Shield AS

(Collectively, “Abbott Norway”)

Abbott’s approach to human rights (which includes the identification of and ways to address modern slavery risk) is directed and guided by Abbott. This is aimed at ensuring a consistent approach across all Abbott companies.

Abbott is committed to upholding the fundamental principles of human rights, labor, environmental protection and anti-corruption to ensure long-term business success for Abbott and to improve lives around the world. Our Position Statement on Human Rights sets out our commitment to human rights and is supported by our Code of Conduct and

supplier guidelines as it relates to our operations and supply chain, respectively.^[1]

As set out in our position statement, Abbott believes in the dignity of every human being and respects individual rights as set forth in the United Nations Universal Declaration of Human Rights (UDHR) and Guiding Principles on Business and Human Rights (UNGPs). Our Position Statement on Human Rights can be found here:

https://dam.abbott.com/en-us/documents/pdfs/transparency/Position_Statement_on_Human_Rights_FINAL_v2.pdf

^[1] Supplier Guidelines: [Supplier-Guidelines-FINAL-ENGLISH.pdf](https://dam.abbott.com/en-us/documents/pdfs/transparency/Supplier-Guidelines-FINAL-ENGLISH.pdf) (abbott.com)

Abbott recognizes that companies play a supporting role in promoting human rights within their sphere of influence. We contribute to the fulfilment of human rights through compliance with laws and regulations wherever we operate, as well as through our policies and programs. Abbott's Position Statement on Human Rights is reinforced in our employment, ethics and procurement policies, which are designed to promote, protect and respect human rights within Abbott and with our suppliers.

Abbott Norway is headquartered in Oslo. At the date of this statement, Abbott Norway's workforce consists of approximately 400 employees.

Abbott is a multinational business which procures goods and services from approximately 89,000 suppliers in 163 countries. In 2022, Abbott spent approximately \$23 billion with these suppliers.

Our management approach places particular importance on supply chain sustainability and resilience. We maintain a multilayered governance structure that provides oversight of supply chain-related activities, helping minimize risks and maximize opportunities to address shared impacts. Each business is responsible for their respective supply chain, with enterprise efforts coordinated through Abbott's Global Operations Council (GOC).

The GOC collaborates across the enterprise to set the framework for our supply chain, encompassing procurement, manufacturing and logistics to improve supply chain adaptability, resilience and flexibility.

POLICES AND TRAINING

Our approach to identifying, assessing, addressing and managing human rights is guided by company-wide policies and processes. These policies and processes are embedded across our business (including Abbott Norway) and, in relation to our supply chains, are overseen by the GOC. This ensures a consistent approach towards mitigating human rights risk.

Abbott Norway, as a member of Abbott's global supply chain, relies on intragroup processes to assess and address its human rights risk.

The policies and processes in the table on the next page detail the actions in place to assess and address human rights. More detailed descriptions of our activities in this area are also available in our most recent Global Sustainability Report, available at:

www.abbott.com/responsibility/sustainability/sustainability-reporting/current-reports.html

Unless otherwise stated, these policies and processes are applied across Abbott's global supply chain, including the entities covered by this statement.

Every Abbott employee is expected to adhere to all laws and Abbott's policies, procedures, principles and standards. Abbott employees are obliged to comply with Abbott's Code of Business Conduct. Our Code of Business Conduct includes prohibitions on illegal and inappropriate labor conditions and cruel or inhumane treatment.

Policies and Practices That Support Our Efforts on Sustainability

Code of Business Conduct	Code of Business Conduct Governance Investors (abbott.com)
Position Statement on Human Rights	Other Disclosures Policies Abbott U.S.
Supplier Guidelines	Suppliers Products and Services Abbott U.S.
Diversity and Inclusion	Diversity and Inclusion Abbott U.S.
Discrimination, Bullying, Harassment and Grievance	Abbott Statement on Racial Inequality Abbott Newsroom
Incident Reporting and Investigations	EthicsPoint - Abbott Laboratories

In addition to Code of Conduct training, employees must also complete global anti-corruption training annually to ensure we continue to conduct business the right way.

Our supplier guidelines establish expectations for suppliers we work with, aligning with internationally recognized and industry-accepted guidelines, such as the Pharmaceutical Supply Chain Initiative (PSCI) Principles for Responsible Supply Chain Management. Our guidelines focus on the following priorities:

- Management systems
- Human rights and labor
- Health and safety
- Ethics
- Environmental management and compliance
- Supply chain management

Through the guidelines, we detail our expectations that suppliers conduct business in compliance with relevant legal requirements and industry codes. When asked, suppliers are expected to

demonstrate compliance at the request and to the satisfaction of Abbott through our Supplier Social Responsibility Program. We expect suppliers to fully support the guidelines, driving sustainability principles into their own supply chains, systems and employee practices. Our tier 1 suppliers are expected to cascade the values represented in our supplier guidelines into their own supply chains and drive responsible sourcing practices to Abbott's tier 2 suppliers and beyond.

We monitor compliance with the guidelines through our Supplier Social Responsibility Program and contracting process, and we work with suppliers to improve their performance, where required, through both global and strategic programming. Suppliers are required to maintain documentation necessary to demonstrate conformance with the supplier guidelines and compliance with applicable laws, regulations, rules, ordinances, permits, licenses, approvals and orders.

Suppliers must be able to demonstrate compliance with our guidelines at our request and to the satisfaction of Abbott through our Supplier Social Responsibility Program. It is Abbott's expectation that our suppliers fully support the guidelines and drive sustainability principles across their own supply chains, systems and employee benefits. This helps ensure materials and services from tier 2 suppliers also meet our requirements.

We also embed a social responsibility clause in our direct material procurement contracts. The clause details Abbott's values and sets the expectation that vendors will comply with the focus areas of our supplier guidelines. It enables assessment of this compliance and requires our vendors to remediate any issues identified.



Our due diligence and risk assessment processes not only aim to identify human rights risk, but they also assist us to assess and address this risk. These processes evaluate suppliers for potential sustainability issues, including those related to ethics, human rights and labor, health and safety, environment, and management systems.

When selecting suppliers, we consider applicable environmental, social and governance (ESG) factors alongside business capabilities and capacities, financial health, and alignment with our vision.

Our supplier assessment programs take a risk-based approach to screening, assessment and monitoring, considering supplier size, industry, sourcing location(s), ESG performance and Abbott spend.

We continue to identify and mitigate potential human rights impacts across our operations and supply chain, including risks of

discrimination and unequal pay; unsafe working conditions; human trafficking; child labor; and forced or bonded labor. As detailed further below, Abbott conducts periodic reviews of our risk exposure, including annual high-level risk assessments of our global supply base.

SUSTAINABILITY RISK SCREENING

During 2022, we took several steps to enhance our global process. This includes adopting additional third-party supply chain sustainability risk-mapping technology to assess and provide a more detailed understanding of our direct supplier's sustainability risks.

These tools assign sustainability risk intensity factors based upon a supplier's industry and region through referencing a variety of public and nonprofit sustainability, geopolitical, security, and infrastructure indices and sources.

We engage with our suppliers of potentially high sustainability risk to explore compliance with our supplier guidelines. Desktop assessments, conducted by a third party, are tailored to the nature of the supplier's operations, location and size. Assessments cover the topics of labor and human rights, environment and sustainable procurement.

On-site audits are conducted by an external auditor using a workplace condition report or other globally recognized sustainability audit standards to assess social and labor conditions, and health and safety, environment, and business practices at the site.

Additional risk-specific analyses are performed for strategic sourcing categories and regions when potential risks are identified. Insights from these programs then inform our sourcing strategy and contingency plans.



We also address human rights risk in our other business relationships, including through our Third-Party Compliance Process, which requires Abbott businesses, subsidiaries and affiliates outside the U.S. to complete due diligence before engaging third-party companies. This includes screening companies, identifying high-risk partners, and monitoring and mitigating any potential risks.

Where major issues are noted, suppliers must submit corrective and preventive action (CAPA) plans within 30–60 days of receiving audit results. Abbott’s supplier relationship manager and subject matter experts will then monitor the supplier’s CAPA implementation and determine if a reaudit or other action, such as contract termination, is required. We also encourage suppliers to report concerns via our “Speak Up” Program described in the section at right.

In addition to our Supplier Sustainability Survey and Audit Program, we maintain category- and region-specific supplier assessment and audit programs where specific sustainability risks have been identified.

ACCOUNTABILITY

We require our suppliers to comply with all applicable legal requirements and industry codes to do business with Abbott.

When acting on behalf of Abbott, we expect our suppliers to act in an open and honest manner with third parties. Business decisions must not be improperly influenced by personal interests or relationships, including personal or non-Abbott business relationships with Abbott employees.

Our guidelines provide that any concern a supplier has regarding unethical conduct or a potential conflict of interest be reported through Abbott’s Office of Ethics and Compliance at <http://speakup.abbott.com>.

Abbott’s Supplier Guidelines are made available in multiple languages and can be found here: <https://www.abbott.com/partners/suppliers.html>.

We continue to refine and improve our approach to assessing effectiveness. For financial year 2022, Abbott (which includes Abbott Norway) assessed the effectiveness of its actions in the following ways.



In Q4 2022, Abbott completed inherent sustainability risk screening of strategic suppliers utilizing a third-party supply chain sustainability risk screening technology to assign sustainability risk intensity factors based on a supplier's industry and region. Through this exercise, we screened 88% of spend affiliated with raw materials, components and services that are directly traceable to Abbott's final finished products. Results of this preliminary screening drove prioritization and supplier engagements in 2023.

In 2022, we continued partnering with suppliers from key sourcing categories, engaging more than 3,900 suppliers on sustainability risks and opportunities and influencing more than 49% of our supply chain spend. These activities addressed 260 potential high-sustainability-risk suppliers through desktop assessments and 74 high sustainability risk suppliers through sustainability audits.

Through our 2022 audit programs, we engaged with seven suppliers to implement corrective actions to address employee health and safety, environment, and supply chain management issues.

For Norway, in 2022 and 2023, we continued partnering with suppliers from key sourcing categories to understand our supply chain sustainability risks. We conducted inherent risk screening of direct and select indirect suppliers sourcing into or out of Norway. Our findings indicate that there is limited social sustainability risk where employee health/safety and materials, chemicals and waste were identified as potential risks which require further engagement with our suppliers. Given the breadth and complexity of our supply chain, these risks may change over time.

A select set of these suppliers with higher potential for risk exposure are engaged through desktop assessments for further analysis. 2022 and 2023 activities have addressed 16 potential high-sustainability-risk suppliers through desktop assessments or surveys and one high-sustainability-risk supplier through on-site sustainability audits.

Abbott offers several channels where questions can be asked and concerns can be raised, including via our "Speak Up" Program. Our Ethics and Compliance helpline is multilingual and available globally 24/7 where there are concerns of a potential violation of Abbott's values and standards of conduct. <http://speakup.abbott.com>

This statement has been approved and signed by the directors of the entities covered by this statement.

© 2023 Abbott. Unless otherwise noted, all product and service names appearing in this document are trademarks owned or licensed by Abbott, its subsidiaries, or affiliates.